The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2021 | MDS: QoL considerations
Sara Tinsley-Vance, PhD, APRN, Moffitt Cancer Center, Florida, USA, describes the quality of life (QOL) of patients with myelodysplastic syndromes (MDS). Dr Tinsley-Vance explains that although there are tools to measure the QOL, it is highly subjective and it is thus crucial to ask the patient about their own needs. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.
Disclosures
Sara Tinsley-Vance, PhD, APRN, discloses links to Bristol Myers Squibb, Jazz and Novartis.
